Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 94

1.

The potential for QT prolongation and pro-arrhythmia by non-anti-arrhythmic drugs: clinical and regulatory implications. Report on a Policy Conference of the European Society of Cardiology.

Haverkamp W, Breithardt G, Camm AJ, Janse MJ, Rosen MR, Antzelevitch C, Escande D, Franz M, Malik M, Moss A, Shah R.

Cardiovasc Res. 2000 Aug;47(2):219-33. No abstract available.

PMID:
10947683
2.

The potential for QT prolongation and proarrhythmia by non-antiarrhythmic drugs: clinical and regulatory implications. Report on a policy conference of the European Society of Cardiology.

Haverkamp W, Breithardt G, Camm AJ, Janse MJ, Rosen MR, Antzelevitch C, Escande D, Franz M, Malik M, Moss A, Shah R.

Eur Heart J. 2000 Aug;21(15):1216-31. Review. No abstract available.

PMID:
10924311
3.

Drugs that cause Torsades de pointes and increase the risk of sudden cardiac death.

Wolbrette DL.

Curr Cardiol Rep. 2004 Sep;6(5):379-84. Review.

PMID:
15306095
4.
5.

Postmarketing reports of QT prolongation and ventricular arrhythmia in association with cisapride and Food and Drug Administration regulatory actions.

Wysowski DK, Corken A, Gallo-Torres H, Talarico L, Rodriguez EM.

Am J Gastroenterol. 2001 Jun;96(6):1698-703.

PMID:
11419817
6.

[Minimizing the risks associated with QTc prolongation in people with schizophrenia. A consensus statement by the Cardiac Safety in Schizophrenia Group].

Ames D, Camm J, Cook P, Falkai P, Gury C, Hurley R, Johnson G, Piepho R, Vieweg V; Cardiac Safety in Schizophrenia Group.

Encephale. 2002 Nov-Dec;28(6 Pt 1):552-62. French.

PMID:
12506268
7.

Drug-induced QT interval prolongation--regulatory guidance and perspectives on hERG channel studies.

Shah RR.

Novartis Found Symp. 2005;266:251-80; discussion 280-5. Review.

PMID:
16050273
8.

Pharmacologic agents associated with QT interval prolongation.

Olsen KM.

J Fam Pract. 2005 Jun;Suppl:S8-S14. Review.

PMID:
15938993
9.
10.

Clinical characteristics of patients with drug-induced QT interval prolongation and torsade de pointes: identification of risk factors.

Letsas KP, Efremidis M, Kounas SP, Pappas LK, Gavrielatos G, Alexanian IP, Dimopoulos NP, Filippatos GS, Sideris A, Kardaras F.

Clin Res Cardiol. 2009 Apr;98(4):208-12. doi: 10.1007/s00392-008-0741-y. Epub 2008 Nov 24.

PMID:
19031039
11.

Antidepressants: their effects on cardiac channels, QT prolongation and Torsade de Pointes.

Sala M, Coppa F, Cappucciati C, Brambilla P, d'Allio G, Caverzasi E, Barale F, De Ferrari GM.

Curr Opin Investig Drugs. 2006 Mar;7(3):256-63. Review.

PMID:
16555686
12.

Frequency of high-risk use of QT-prolonging medications.

Allen LaPointe NM, Curtis LH, Chan KA, Kramer JM, Lafata JE, Gurwitz JH, Raebel MA, Platt R.

Pharmacoepidemiol Drug Saf. 2006 Jun;15(6):361-8.

PMID:
16178046
13.
14.

Gender differences in the proarrhythmic potential of QT-prolonging drugs.

Wolbrette D.

Curr Womens Health Rep. 2002 Apr;2(2):105-9. Review.

PMID:
12116598
15.

[Cardiac effects of antipsychotics: mechanism of arrhythmias and sudden cardiac death].

Kecskeméti V.

Neuropsychopharmacol Hung. 2004 Mar;6(1):5-12. Review. Hungarian.

PMID:
15125308
16.

Drug induced QT prolongation and torsades de pointes.

Yap YG, Camm AJ.

Heart. 2003 Nov;89(11):1363-72. Review. No abstract available.

17.

[QTc-prolonging drugs and the risk of sudden death].

Reingardiene D, Vilcinskaite J.

Medicina (Kaunas). 2007;43(4):347-53. Review. Lithuanian.

18.

Understanding drug-induced torsades de pointes: a genetic stance.

Kannankeril PJ.

Expert Opin Drug Saf. 2008 May;7(3):231-9. doi: 10.1517/14740338.7.3.231 . Review.

PMID:
18462182
19.

The canine Purkinje fiber: an in vitro model system for acquired long QT syndrome and drug-induced arrhythmogenesis.

Gintant GA, Limberis JT, McDermott JS, Wegner CD, Cox BF.

J Cardiovasc Pharmacol. 2001 May;37(5):607-18.

PMID:
11336111

Supplemental Content

Support Center